Atossa Genetics believes it can prevent breast cancer by 2020 — and in the meantime, capture a unique market opportunity — with their novel cellular and molecular diagnostic risk assessment products for early detection. Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?
Atossa Genetics [Nasdaq: ATOS] is a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer through the detection of precursors to breast cancer.
DARA Biosciences has created some buzz as of late, landing on several ‘watch lists’ after the company’s exclusive licensing of three market-ready products for distribution in the United States. CEO/Chief Medical Officer Dr. David Drutz and COO Chris Clement conducted a two-part interview with OneMedRadio discussing developmental milestones and key catalysts for Q4-2012 and 2013.
To date, most CTC capture and detection technologies have not been able to recognize the cytokeratin negative (CK‐) CTCs. Biocept’s Cell Enrichment and Extraction (CEETM) platform allows for the capture of these CK- cells as well as CK+ CTC phenotypes
In 2010, NCI estimated that 207,090 women were diagnosed with breast cancer, while 39,840 women likely died from the disease.
Neo Matrix is a medical devices company that has developed a novel diagnostic test to determine breast cancer risk. The company’s test uses breast fluid to analyze the presence of normal, pre-malignant […]
Seno Medical is a company focused on cancer using its new patented opto-acoustic technology. This new imaging modality combines the use of light in and sound out to uniquely obtain the hallmark […]
Scientists have yet to find the magic cure for cancer, but they may have found a way to beat it at its own game.